Magnolia Medical Technologies Introduces Steripath ISDD Study Results
Seattle, March 5, 2025 /PRNewswire/ — Magnolia Medical Technologies, Inc., a leader in Initial Specimen Diversion Device® (ISDD®) technology, has unveiled groundbreaking findings from a recent study. The study, conducted by researchers at the University of Nebraska Medical Center (UNMC) and published in the prestigious journal Infection Control & Hospital Epidemiology, highlights the potential of the Steripath® ISDD in improving the accuracy of blood cultures drawn from central venous catheters (CVCs).
The study compared blood cultures drawn using standard methods with those drawn using the Steripath ISDD in a simulated CVC colonization and contamination model. The results were significant: the Steripath ISDD technology detected 100% of colonized CVCs while reducing false-positive cultures by 56%. This development could have a profound impact on the diagnostic precision of bloodstream infection detection, particularly for critically ill patients relying on CVCs.
Dr. Mark E. Rupp, Professor and Interim Chair at the University of Nebraska Medical Center, emphasized the importance of accurately identifying patients with sepsis and bloodstream infections. He noted that the study’s findings suggest that the Steripath ISDD may enhance the accuracy of blood cultures drawn from central vascular catheters, leading to more informed treatment decisions and improved patient outcomes.
The research builds on existing evidence supporting the clinical impact of Steripath ISDD devices in preventing false-positive blood cultures for peripheral venipunctures and IV starts. A landmark study at Stanford University Medical Center showed that the use of Steripath reduced blood culture contamination to 0% in over 11,200 cultures, significantly decreasing false-positive central line-associated bloodstream infections.
The findings from the UNMC study suggest a potential paradigm shift in blood culture collection. The Steripath ISDD technology could play a crucial role in improving the reliability of this critical microbiology test, helping clinicians differentiate true infections from contamination events.
Magnolia Medical Technologies is dedicated to revolutionizing blood culture collection with scientifically validated innovations. The company continues to collaborate with healthcare institutions to expand access to Steripath ISDD technology nationwide.
About Steripath
The Steripath ISDD platform offers FDA-cleared devices designed to reduce blood culture contamination. Over 20 clinical studies support the clinical and cost effectiveness of Steripath, with nine peer-reviewed publications in leading journals.
Steripath and Steripath Micro have been adopted by over 500 U.S. hospitals to address blood culture contamination issues, potentially saving billions of dollars annually in healthcare costs.
About Magnolia Medical Technologies
Magnolia Medical Technologies develops innovative collection devices to improve the accuracy of critical laboratory tests. The company’s patented ISDT and ISDD technologies prevent blood culture contamination, with a robust intellectual property portfolio covering hundreds of devices and concepts.
In conclusion, the study’s findings on the Steripath ISDD’s potential to enhance blood culture accuracy are significant. By improving diagnostic precision and reducing false positives, the technology could lead to better patient outcomes and significant cost savings in healthcare. For more information on this groundbreaking study and Magnolia Medical Technologies’ innovative solutions, visit their website.
